Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells.
Abstract: Ivermectin is currently approved for treatment of both clinical and veterinary infections by nematodes, including Onchocerca cervicalis in horses and Onchocerca volvulus in humans. However, ivermectin has never been shown to be effective against bacterial pathogens. Here we show that ivermectin also inhibits infection of epithelial cells by the bacterial pathogen, Chlamydia trachomatis, at doses that could be envisioned clinically for sexually-transmitted or ocular infections by Chlamydia.
Publication Date: 2012-10-30 PubMed ID: 23119027PubMed Central: PMC3484050DOI: 10.1371/journal.pone.0048456Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- N.I.H.
- Extramural
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article assesses the potential of Ivermectin, a medicine typically used to treat infections caused by nematodes, in curbing the growth of the bacterial pathogen, Chlamydia trachomatis, in epithelial cells.
Objective of the Research
- The research aimed to explore the effectiveness of Ivermectin, which has been traditionally used for treating nematode infections, in treating bacterial infections, particularly those caused by Chlamydia trachomatis.
Findings of the Study
- The study found that Ivermectin can successfully inhibit the growth of Chlamydia trachomatis in epithelial cells. This is a significant result considering that Ivermectin has never been observed to be effective against bacterial pathogens before.
Clinical Relevance
- This discovery suggests that Ivermectin could possibly be used clinically for treating sexually-transmitted or ocular infections caused by Chlamydia. Its ability to suppress infection at conceivable clinical doses makes it a promising candidate for such treatments.
Implications of the Study
- This research opens new doors for using Ivermectin in a broader medicinal context, extending its use beyond nematode infections. The usage of a drug already approved gives an advantage in bringing it clinically to market more quickly for this new usage aas the safety profile already known.
- The discovery might necessitate future in-depth studies into the effects and mechanisms of Ivermectin on various bacterial infections, enabling a more effective and targeted use of the medicine.
Cite This Article
APA
Pettengill MA, Lam VW, Ollawa I, Marques-da-Silva C, Ojcius DM.
(2012).
Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells.
PLoS One, 7(10), e48456.
https://doi.org/10.1371/journal.pone.0048456 Publication
Researcher Affiliations
- Molecular Cell Biology, Health Sciences Research Institute, University of California Merced, United States of America.
MeSH Terms
- Anti-Bacterial Agents / pharmacology
- Chlamydia trachomatis / drug effects
- Chlamydia trachomatis / physiology
- Epithelial Cells / microbiology
- HeLa Cells
- Humans
- Ivermectin / pharmacology
Grant Funding
- R01 AI079004 / NIAID NIH HHS
- R01 DE019444 / NIDCR NIH HHS
Conflict of Interest Statement
The authors have read the journal’s policy and have the following conflicts: Co-author DMO is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
References
This article includes 18 references
- Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, Kong YL, Monaghan RL, Olson G, Putter I, Tunac JB, Wallick H, Stapley EO, Oiwa R, Omura S. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation.. Antimicrob Agents Chemother 1979 Mar;15(3):361-7.
- Egerton JR, Ostlind DA, Blair LS, Eary CH, Suhayda D, Cifelli S, Riek RF, Campbell WC. Avermectins, new family of potent anthelmintic agents: efficacy of the B1a component.. Antimicrob Agents Chemother 1979 Mar;15(3):372-8.
- Miller TW, Chaiet L, Cole DJ, Cole LJ, Flor JE, Goegelman RT, Gullo VP, Joshua H, Kempf AJ, Krellwitz WR, Monaghan RL, Ormond RE, Wilson KE, Albers-Schönberg G, Putter I. Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties.. Antimicrob Agents Chemother 1979 Mar;15(3):368-71.
- Chabala JC, Mrozik H, Tolman RL, Eskola P, Lusi A, Peterson LH, Woods MF, Fisher MH, Campbell WC, Egerton JR, Ostlind DA. Ivermectin, a new broad-spectrum antiparasitic agent.. J Med Chem 1980 Oct;23(10):1134-6.
- Omura S, Crump A. The life and times of ivermectin - a success story.. Nat Rev Microbiol 2004 Dec;2(12):984-9.
- Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis.. Lancet 2010 Oct 2;376(9747):1175-85.
- Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I. Oral ivermectin versus malathion lotion for difficult-to-treat head lice.. N Engl J Med 2010 Mar 11;362(10):896-905.
- Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies.. N Engl J Med 2010 Feb 25;362(8):717-25.
- Bavoil PM, Hsia RC, Ojcius DM. Closing in on Chlamydia and its intracellular bag of tricks.. Microbiology (Reading) 2000 Nov;146 ( Pt 11):2723-2731.
- Fields KA, Hackstadt T. The Chlamydia Type III Secretion System: Structure and Implications for Pathogenesis. 2006;219–233.
- Wyrick PB. Intracellular survival by Chlamydia.. Cell Microbiol 2000 Aug;2(4):275-82.
- Belland R, Ojcius DM, Byrne GI. Chlamydia.. Nat Rev Microbiol 2004 Jul;2(7):530-1.
- Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus.. Eur J Clin Pharmacol 1996;50(5):407-10.
- Gokbulut C, Cirak VY, Senlik B, Aksit D, Durmaz M, McKellar QA. Comparative plasma disposition, bioavailability and efficacy of ivermectin following oral and pour-on administrations in horses.. Vet Parasitol 2010 May 28;170(1-2):120-6.
- Adelsberger H, Lepier A, Dudel J. Activation of rat recombinant alpha(1)beta(2)gamma(2S) GABA(A) receptor by the insecticide ivermectin.. Eur J Pharmacol 2000 Apr 14;394(2-3):163-70.
- North RA. Molecular physiology of P2X receptors.. Physiol Rev 2002 Oct;82(4):1013-67.
- Pettengill MA, Marques-da-Silva C, Avila ML, d'Arc dos Santos Oliveira S, Lam VW, Ollawa I, Abdul Sater AA, Coutinho-Silva R, Häcker G, Ojcius DM. Reversible inhibition of Chlamydia trachomatis infection in epithelial cells due to stimulation of P2X(4) receptors.. Infect Immun 2012 Dec;80(12):4232-8.
- Pettengill MA, Lam VW, Ojcius DM. The danger signal adenosine induces persistence of chlamydial infection through stimulation of A2b receptors.. PLoS One 2009 Dec 14;4(12):e8299.
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
